a public good project by the
Synthesis
Company
of California

© 2026

Characterization of Site-Specific Glycation During Process Development of a Human Therapeutic Monoclonal Antibody | doi.page

0 citations0 references

Google Scholar doi.org

Characterization of Site-Specific Glycation During Process Development of a Human Therapeutic Monoclonal Antibody

Journal of Pharmaceutical Sciences·2011·Vol. 100(7), pp. 2543–2550

Citations Over TimeTop 10% of 2011 papers

Amanda Miller, David M. Hambly, Bruce A. Kerwin, Michael J. Treuheit, Himanshu S. Gadgil

Related Papers

→ Advanced Glycation End-Products (AGEs) and Their Soluble Receptor (sRAGE) in Women Suffering from Systemic Lupus Erythematosus (SLE)(2021)22 cited
→ Identification of Nω-Carboxymethylarginine, a New Advanced Glycation Endproduct in Serum Proteins of Diabetic Patients: Possibility of a New Marker of Aging and Diabetes(2001)56 cited
→ Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats(1996)44 cited
→ Renal clearance of glycation adducts: anti-glycation defence in uraemia and dialysis(2003)10 cited
[The role of glycation in cataract lens in diabetic patients].(1998)